Kodiak Sciences's - KOD market analysis on 3rd March 2021

Transaction Date	Recipient	Shares	Type	Price	Value
22nd February 2021	Jason Ehrlich	1,611	Open or private sale	$125.97	$202,940.73
22nd February 2021	Jason Ehrlich	2,150	Open or private sale	$124.92	$268,573.92
22nd February 2021	Jason Ehrlich	413	Open or private sale	$129.18	$53,349.61
22nd February 2021	Jason Ehrlich	1,827	Open or private sale	$127.34	$232,650.36
22nd February 2021	Jason Ehrlich	262	Open or private sale	$122.00	$31,963.66
22nd February 2021	Jason Ehrlich	687	Open or private sale	$123.56	$84,888.61
22nd February 2021	Jason Ehrlich	6,950	Exercise of derivative	$10.29	$71,515.50
17th February 2021	Bros. Advisors Lp Baker	5,792,538	Open or private purchase	$16.00	$92,680,608.00
17th February 2021	Bros. Advisors Lp Baker	457,462	Open or private purchase	$16.00	$7,319,392.00
20th January 2021	Jason Ehrlich	2,061	Open or private sale	$163.10	$336,139.21

Kodiak Sciences

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company. The company engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; K SI-501 for DME and uveitis.

Ticker: KOD

Sector: Health Technology

Industry: Biotechnology

SEC Central Index Key (CIK): 1468748

Employees: 39

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis